145 related articles for article (PubMed ID: 28671946)
1. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.
Ogata T; Nakamura M; Sang M; Yoda H; Hiraoka K; Yin D; Sang M; Shimozato O; Ozaki T
PLoS One; 2017; 12(7):e0179884. PubMed ID: 28671946
[TBL] [Abstract][Full Text] [Related]
2. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
3. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death.
Nakamura M; Sugimoto H; Ogata T; Hiraoka K; Yoda H; Sang M; Sang M; Zhu Y; Yu M; Shimozato O; Ozaki T
Oncogenesis; 2016 Jun; 5(6):e233. PubMed ID: 27294865
[TBL] [Abstract][Full Text] [Related]
4. Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
Sang M; Nakamura M; Ogata T; Sun D; Shimozato O; Nikaido T; Ozaki T
Oncol Rep; 2018 Jun; 39(6):2749-2758. PubMed ID: 29620279
[TBL] [Abstract][Full Text] [Related]
5. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Discov; 2015; 1():15010. PubMed ID: 27551445
[TBL] [Abstract][Full Text] [Related]
6. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
[TBL] [Abstract][Full Text] [Related]
7. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Dis; 2015 Oct; 6(10):e1914. PubMed ID: 26469963
[No Abstract] [Full Text] [Related]
8. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
Vrana JA; Decker RH; Johnson CR; Wang Z; Jarvis WD; Richon VM; Ehinger M; Fisher PB; Grant S
Oncogene; 1999 Nov; 18(50):7016-25. PubMed ID: 10597302
[TBL] [Abstract][Full Text] [Related]
10. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
Ozaki T; Wu D; Sugimoto H; Nagase H; Nakagawara A
Cell Death Dis; 2013 Apr; 4(4):e610. PubMed ID: 23618908
[TBL] [Abstract][Full Text] [Related]
11. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer.
Kayed H; Jiang X; Keleg S; Jesnowski R; Giese T; Berger MR; Esposito I; Löhr M; Friess H; Kleeff J
Br J Cancer; 2007 Oct; 97(8):1106-15. PubMed ID: 17876328
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
14. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
15. Functions of TAp63 and p53 in restraining the development of metastatic cancer.
Tan EH; Morton JP; Timpson P; Tucci P; Melino G; Flores ER; Sansom OJ; Vousden KH; Muller PA
Oncogene; 2014 Jun; 33(25):3325-33. PubMed ID: 23873029
[TBL] [Abstract][Full Text] [Related]
16. Plk1 regulates liver tumor cell death by phosphorylation of TAp63.
Komatsu S; Takenobu H; Ozaki T; Ando K; Koida N; Suenaga Y; Ichikawa T; Hishiki T; Chiba T; Iwama A; Yoshida H; Ohnuma N; Nakagawara A; Kamijo T
Oncogene; 2009 Oct; 28(41):3631-41. PubMed ID: 19668228
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.
Muller PA; Trinidad AG; Caswell PT; Norman JC; Vousden KH
J Biol Chem; 2014 Jan; 289(1):122-32. PubMed ID: 24220032
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
20. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
